COMMUNIQUÉS West-GlobeNewswire

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
31/03/2026
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual [...]
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
31/03/2026
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a [...]
TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives
31/03/2026
FREDERICK, Md., March 31, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® ( [...]
Cognition Therapeutics CEO Issues Letter to Shareholders
31/03/2026
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, [...]
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
31/03/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium [...]
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
31/03/2026
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H2 2026 Cash runway [...]
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
31/03/2026
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer [...]
BioAtla Announces Share Consolidation
31/03/2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody [...]
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
31/03/2026
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
31/03/2026
POMPANO BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
Axe Compute Inc. Reports Full-Year 2025 Financial Results
31/03/2026
Completed Strategic Transformation to AI Compute Infrastructure Raised $343.5 Million in Capital to Fund Digital Asset Treasury Strategy Solidified new leadership composition with world class CEO and board members [...]
NeuroSalt Claims Evaluated: What the Pink Salt Trick Research Says About Neuro Salt Supplementation for Nerve Health
31/03/2026
An informational overview of NeuroSalt ingredients, pink salt trick marketing claims, nerve pain supplement research context, pricing, refund policy, and what to know before buying Neuro Salt in 2026 Lakeland, FL, March [...]
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
31/03/2026
WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile
31/03/2026
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At a median follow-up [...]
Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
31/03/2026
Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE [...]
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
31/03/2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
31/03/2026
PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“ BriaCell ”), a clinical-stage biotechnology company that [...]
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2025
31/03/2026
Le programme de développement global de JNJ-1900 (NBTXR3) a progressé comme prévu, ouvrant la voie à une opportunité d’adresser l’un des plus grands marchés encore inexploités en oncologie grâce aux programmes les plus [...]

Pages